Last reviewed · How we verify
aml according to who 2016 classification except acute promyelocytic leukemia and refractory to induction therapy or relapsed after first line treatment
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- aml according to who 2016 classification except acute promyelocytic leukemia and refractory to induction therapy or relapsed after first line treatment patent landscape — cliff calendar, originator estates, attackable patents
- aml according to who 2016 classification except acute promyelocytic leukemia and refractory to induction therapy or relapsed after first line treatment treatment landscape brief
- aml according to who 2016 classification except acute promyelocytic leukemia and refractory to induction therapy or relapsed after first line treatment treatment updates RSS
Related
- Treatment landscape: aml according to who 2016 classification except acute promyelocytic leukemia and refractory to induction therapy or relapsed after first line treatment patent cliff · aml according to who 2016 classification except acute promyelocytic leukemia and refractory to induction therapy or relapsed after first line treatment CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing